Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.

May Yee ChoiDaniel LiCandace H FeldmanKazuki YoshidaHongshu GuanSeoyoung C KimBrendan M EverettKaren H Costenbader

Published in: Rheumatology (Oxford, England) (2021)

In this head-to-head PS-matched analysis, CVD event risks among SLE patients starting MMF vs CYC or AZA were not statistically reduced except in one 12-month ITT analysis of MMF vs AZA, suggesting longer-term use may convey benefit. Further studies of potential cardioprotective benefit of MMF are necessary.

Keyphrases

systemic lupus erythematosus
cardiovascular disease
human health
end stage renal disease
newly diagnosed
chronic kidney disease
disease activity
preterm infants
prognostic factors
risk assessment
peritoneal dialysis
patient reported outcomes
cardiovascular events
cardiovascular risk factors
patient reported